

This listing of claims will replace all prior versions, and listings, of claims in the application:

Claim 1 (currently amended): ~~A protein~~ An isolated antibody comprising an immunoglobulin heavy chain (HC) variable domain and an immunoglobulin light chain (LC) variable domain, wherein the HC variable domain and the LC variable domain form an antigen binding site that binds to an activated conformation of LFA-1, wherein the ~~antibody protein~~ has one or more of the following properties:

(i) the heavy chain variable domain comprises:

(a) a CDR1 that comprises RYVMW (SEQ ID NO:1);

(b) a CDR2 that comprises YIWPSGGNTYYADSVKG (SEQ ID NO:2);  
~~and/or~~ and

(c) a CDR3 that comprises Xa-S-X2-D-X4-X5-S-X7-A-X8-X9-X10-X11  
(SEQ ID NO:4), and Xa is S or N; X2 is Y or F; X4 is hydrophobic; X5 is  
W or R; X7 is N or Y; X9 is Y or F; X10 is D, E or A; and X11 is any  
amino acid SYDFWSNAFDI (SEQ ID NO:3);

(ii) the light chain variable domain comprises

(a) a CDR1 that comprises RASQSIGSYLN (SEQ ID NO:7);

(b) a CDR2 that comprises AASSLQS (SEQ ID NO:8); ~~and/or~~ and

(c) a CDR3 that comprises QQSYSTPS (SEQ ID NO:9);

(iii) the heavy chain variable domain comprises SEQ ID NO:23, SEQ ID NO:25,  
SEQ ID NO:27, or SEQ ID NO:29;

(iv) the light chain variable domain comprises SEQ ID NO:22, SEQ ID NO:24,  
SEQ ID NO:26, or SEQ ID NO:28;

(v) the heavy chain variable domain comprises a sequence encoded by a nucleic  
acid that hybridizes under high stringent conditions to the full length of SEQ ID  
NO:42, SEQ ID NO:43, or SEQ ID NO:44;

(vi) the light chain variable domain comprises a sequence encoded by a nucleic  
acid that hybridizes under high stringent conditions to the full length of a  
~~sequence that encodes the light chain variable domain of~~ SEQ ID NO: 42, SEQ  
~~ID NO:43, or SEQ ID NO:44~~ SEQ ID NO:39, SEQ ID NO:40, or SEQ ID NO:41;  
~~and/or~~

(vii) the ~~protein which competes with an~~ antibody selected from the group consisting of

- a) an immunoglobulin heavy chain variable domain sequence comprising SEQ ID NO:23, and an immunoglobulin light chain variable domain sequence comprising SEQ ID NO:22;
- b) an immunoglobulin heavy chain variable domain sequence comprising SEQ ID NO:25, and an immunoglobulin light chain variable domain sequence comprising SEQ ID NO:24;
- c) an immunoglobulin heavy chain variable domain sequence comprising SEQ ID NO:27, and an immunoglobulin light chain variable domain sequence comprising SEQ ID NO:26; and
- d) an immunoglobulin heavy chain variable domain sequence comprising SEQ ID NO:29, and an immunoglobulin light chain variable domain sequence comprising SEQ ID NO:28;

for binding to activated LFA-1.

Claim 2 (currently amended): The ~~protein~~ antibody of claim 1 that comprises ~~at least~~ the CDR regions of (i) and (ii).

Claim 3 (currently amended): The ~~protein~~ antibody of claim 1 wherein the heavy and light chain variable domain sequences comprise, respectively, ~~at least~~ SEQ ID NO:23 and SEQ ID NO:22.

Claim 4 (currently amended): The ~~protein~~ antibody of claim 1 wherein at least the protein framework regions are identical to SEQ ID NO:33 (~~heavy chain~~) (light chain) and SEQ ID NO:36 (~~light chain~~) (heavy chain); SEQ ID NO:34 (~~heavy chain~~) (light chain) and SEQ ID NO:37 (~~light chain~~) (heavy chain); or ~~P1-G10~~ SEQ ID NO:35 (light chain) and SEQ ID NO:38 (heavy chain).

Claim 5 (currently amended): The ~~protein~~ antibody of claim 1 wherein the CDR3 of the heavy chain variable domain comprises SYDFWSNAFDI (SEQ ID NO:3) ~~Xa-S-X2-D-~~

X4-X5-S-X7-A-X8-X9-X10-X11 (SEQ ID NO:4), and

- (i) Xa is S or N;
- (ii) X2 is Y or F;
- (iii) X4 is hydrophobic;
- (iv) X5 is W or R;
- (v) X7 is N or Y;
- (vi) X9 is Y or F;
- (vii) X10 is D, E or A; and
- (viii) X11 is any amino acid.

Claim 6 (currently amended): The ~~protein~~ antibody of claim 1 that is not immunogenic in humans.

Claim 7 (currently amended): The ~~protein~~ antibody of claim 1 that is a full length IgG antibody.

Claim 8 (currently amended): The ~~protein~~ antibody of claim 1 that is an antigen binding fragment of an antibody, and does not include an Fc domain.

Claim 9 (currently amended): The ~~protein~~ antibody claim 1 that has at least a 20-fold preference for binding to activated LFA-1 relative to inactivated LFA-1.

Claim 10 (currently amended): ~~A-protein~~ An antibody comprising an immunoglobulin heavy chain (HC) variable domain sequence and an immunoglobulin light chain (LC) variable domain sequence, wherein

- (i) the HC variable domain sequence and the LC variable domain sequence form an antigen binding site that binds to an activated conformation of LFA-1 ("aLFA-1");
- (ii) the protein inhibits ICAM-1 binding to LFA-1 on human peripheral blood mononuclear cells with an IC<sub>50</sub> of less than 5 nM.

Claim 11 (currently amended): A pharmaceutical composition that comprises the ~~protein~~

antibody according to any of claims 1-10 and a pharmaceutically acceptable salt.

Claims 12-33 (canceled)

Claim 34 (new): The antibody of claim 1 wherein the heavy and light chain variable domain sequences comprise, respectively, SEQ ID NO:60 and SEQ ID NO:61.

Claim 35 (new): The antibody of claim 1 comprising SEQ ID NO:33 (light chain) and SEQ ID NO:36 (heavy chain); SEQ ID NO:34 (light chain) and SEQ ID NO:37 (heavy chain); or SEQ ID NO:35 (light chain) and SEQ ID NO:38 (heavy chain).

Claim 36 (new): An isolated antibody comprising an immunoglobulin heavy chain (HC) variable domain and an immunoglobulin light chain (LC) variable domain, wherein the HC variable domain and the LC variable domain form an antigen binding site that binds to an activated conformation of LFA-1, wherein the antibody has one or more of the following properties:

(i) the heavy chain variable domain comprises:

(a) a CDR1 that comprises HYGMS (SEQ ID NO:10)

(b) a CDR2 that comprises VISPSGGRTLYADSVKG (SEQ ID NO:11);

and

(c) a CDR3 that comprises HYSYAMDV (SEQ ID NO:12);

(ii) the light chain variable domain comprises

(a) a CDR1 that comprises TASQSVDSNLA (SEQ ID NO:13);

(b) a CDR2 that comprises GASTRAT (SEQ ID NO:14); and

(c) a CDR3 that comprises QQYNKWPPYS (SEQ ID NO:15);

for binding to activated LFA-1.

Claim 37 (new): An isolated antibody comprising an immunoglobulin heavy chain (HC) variable domain and an immunoglobulin light chain (LC) variable domain, wherein the HC variable domain and the LC variable domain form an antigen binding site that binds to an activated conformation of LFA-1, wherein the antibody has one or more of the

following properties:

(i) the heavy chain variable domain comprises:

(a) a CDR1 that comprises HYSMQ (SEQ ID NO:16)

(b) a CDR2 that comprises VIGSSGGNTYYADSVKG (SEQ ID NO:17);

and

(c) a CDR3 that comprises GTYNTSPFDY (SEQ ID NO:18);

(ii) the light chain variable domain comprises

(a) a CDR1 that comprises SGDALGQKYAS (SEQ ID NO:19);

(b) a CDR2 that comprises QDSKRPS (SEQ ID NO:20); and

(c) a CDR3 that comprises QAWDTTAYV (SEQ ID NO:21);

for binding to activated LFA-1.